Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Phase 4 Completed 25 enrolled The University of Hong Kong Queen Mary Hospital, Hong Kong · collab United Christian Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk of developing progressive renal failure.

Timeline

Start: 2009-07
Primary completion: 2010-12
Completion: 2010-12

Publications

Tang SC, Lin M, Tam S, Au WS, Ma MK, Yap DY, Ho YW, Lai KN. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant. 2012 Feb;27(2):613-8. doi: 10.1093/ndt/gfr349. Epub 2011 Jun 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	300 mg	Oral

Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Summary

Timeline

Publications

Drugs

Indications